Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of Topical Abi-1968 In Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)

NCT03677960 is registered in ClinicalTrials.gov with Antiva Biosciences as lead sponsor.

NCT NCT03677960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03677960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of Topical Abi-1968 In Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)
Lead sponsor
Antiva Biosciences
Phase
Phase 1
Overall status
Terminated
Start date
December 17, 2018
Completion date
June 30, 2019
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, anus neoplasm, hiv infection, hsil, high-grade squamous intraepithelial lesions, human papilloma virus infection